Leiters 🔆 Health

Finished Product Certificate of Analysis

NDC Number:	71449-091-22	Lot Number:	2430139A	
Product Description:	Bevacizumab 2 mg/0.08 mL (25 mg/mL) Repackaged, Ophthalmic Injection, 0.08 mL in 0.25 mL Syringe			
Manufacture Date:	22JAN2024	Expiration Date:	20JUN2024	
Storage Condition:	Refrigerated Temperature (2-8°C), Protect from Light and Freezing			

Test		Method	Acceptance Criteria	Results	Pass/Fail
Sterility		USP <71> and <1223>	No Growth	No Growth	Pass
Post Steriliz Endotoxin	ation	USP <85>	NMT 20.0 EU/mL	<1.0 EU/mL	Pass
Clarity		Visual	Clear	Pass	Pass
Color		Visual	Colorless	Pass	Pass
Visible Parti	culates	USP <790>	Essentially free of visible particulates	Pass	Pass
	≥10 µm		NMT 50 particles/mL	19 Particles/mL	
Particulate	≥25 µm	USP <789>	NMT 5 particles/mL	0 Particles/mL	Pass
	≥50 µm		NMT 2 particles/mL	0 Particles/mL	

All finished product Quality Control test results met acceptance criteria. This batch is suitable for release.

Quality Control Management Disposition of the Batch:		□ Rejected	
Michele Kuhn	Michele Kuhn	QC Manager	07MAR2024
Print Name	Signature	Title	Date